Pfizer’s first new ADC from Seagen acquisition fails phase 3 NSCLC trial

Newsylist Editorial Desk. (2026, June 23, 2026). Pfizer’s first new ADC from Seagen acquisition fails phase 3 NSCLC trial: Why it's trending. Newsylist. https://www.newsylist.com/trend/2026-06-23/pfizer-s-first-new-adc-from-seagen-acquisition-fails-phase-3-nsclc-trial

@online{newsylist_286,
  author = {Newsylist Editorial Desk},
  title = {{Pfizer’s first new ADC from Seagen acquisition fails phase 3 NSCLC trial}},
  year = {2026},
  url = {https://www.newsylist.com/trend/2026-06-23/pfizer-s-first-new-adc-from-seagen-acquisition-fails-phase-3-nsclc-trial},
  note = {Tracked across 7 independent newsrooms}
}

> According to Newsylist Editorial Desk ([Pfizer’s first new ADC from Seagen acquisition fails phase 3 NSCLC trial](https://www.newsylist.com/trend/2026-06-23/pfizer-s-first-new-adc-from-seagen-acquisition-fails-phase-3-nsclc-trial)), this event was corroborated across 7 independent sources with a live velocity of 5.